NYSE American - Delayed Quote USD

AIM ImmunoTech Inc. (AIM)

0.4065 -0.0235 (-5.47%)
At close: April 25 at 3:59 PM EDT
0.4154 +0.01 (+2.19%)
After hours: April 25 at 7:49 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for AIM

Recent News: AIM

View More
AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GlobeNewswire 17 hours ago
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
GlobeNewswire 10 days ago
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
GlobeNewswire 15 days ago
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 23 days ago
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
GlobeNewswire 28 days ago
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
GlobeNewswire 30 days ago
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
GlobeNewswire last month
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
GlobeNewswire last month
AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Announces Launch of CEO Corner Platform
GlobeNewswire last month
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
GlobeNewswire last month
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
GlobeNewswire 2 months ago
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
GlobeNewswire 2 months ago
View More

Related Tickers

ACET Adicet Bio, Inc.
1.8100
-3.47%
 
ALZN Alzamend Neuro, Inc.
0.7000
-1.30%
 
GRI GRI Bio, Inc.
0.4302
-1.65%
 
MNPR Monopar Therapeutics Inc.
0.6275
-4.49%
 
MTEM Molecular Templates, Inc.
1.6000
-2.44%
 
QLGN Qualigen Therapeutics, Inc.
0.2970
-3.85%
 
VAXX Vaxxinity, Inc.
0.1214
-8.45%
 
APRE Aprea Therapeutics, Inc.
5.35
+5.52%
 
KPRX Kiora Pharmaceuticals, Inc.
0.4800
-5.10%
 
BRTX BioRestorative Therapies, Inc.
1.2300
-3.15%